Lithuania vs Netherlands: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Lithuania
87.0%
in 2025
Netherlands
87.0%
in 2025
Lithuania rank
86th
Netherlands rank
86th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Lithuania
- Netherlands
How they compare
Lithuania currently reports 87.0% against 87.0% in Netherlands, a difference of 0.0%.
Across all 18 years both countries report, Netherlands has been ahead every year.
Lithuania ranks 86th and Netherlands ranks 86th of 194 countries.
Netherlands has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 48.0% | 48.0% | Netherlands |
| 2010s | 32.9% | 94.6% | 61.7% | Netherlands |
| 2020s | 83.7% | 89.8% | 6.2% | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Lithuania or Netherlands?
- Lithuania, at 87.0% against 87.0% in Netherlands as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Lithuania and Netherlands?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Netherlands?
- 18 years are reported by both, from 2008 to 2025.
- How do Lithuania and Netherlands rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Lithuania ranks 86th and Netherlands ranks 86th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.